Company Filing History:
Years Active: 2022
Title: The Innovative Contributions of David Stroncek
Introduction
David Stroncek, an accomplished inventor based in Rockville, MD, has made significant contributions to the field of immunotherapy. With one patent to his name, Stroncek's inventive work focuses on methods that advance cancer treatment, specifically through the cultivation of tumor-infiltrating lymphocytes (TIL).
Latest Patents
Stroncek's patent, titled "Methods of growing tumor infiltrating lymphocytes in gas-permeable containers," presents an innovative approach to cancer therapy. This invention details a method for promoting cancer regression in mammals by obtaining a tumor tissue sample, culturing it in a gas-permeable container, and expanding the number of tumor-infiltrating lymphocytes using specific feeder cells. This dual-container method allows for cell expansion before administering the TIL, providing a promising avenue for adoptive cell immunotherapy.
Career Highlights
Throughout his career, David Stroncek has been affiliated with notable organizations, including the Government of the United States of America as represented by the Secretary of the Department of Health and Human Services. He has also worked with Wilson Wolf Manufacturing Corporation, contributing his expertise to advance medical technology and treatment methods in the field of cancer research.
Collaborations
Stroncek has collaborated with esteemed colleagues, including Steven A. Rosenberg and Mark E. Dudley, who are renowned in their respective fields. These collaborations have likely enriched his work and enhanced the impact of his contributions towards innovative cancer therapies.
Conclusion
David Stroncek’s innovative patent stands as a testament to his dedication to enhancing cancer treatment methodologies. His efforts in cultivating tumor-infiltrating lymphocytes encapsulate a critical advancement in immunotherapy, pointing towards a future where such innovative approaches can lead to improved patient outcomes in the fight against cancer.